Printer Friendly

PFIZER ANNOUNCES AVAILABILITY OF ZITHROMAX (AZITHROMYCIN) FIRST ONCE-DAILY FIVE-DAY ORAL ANTIBIOTIC

 PFIZER ANNOUNCES AVAILABILITY OF ZITHROMAX (AZITHROMYCIN)
 FIRST ONCE-DAILY FIVE-DAY ORAL ANTIBIOTIC
 NEW YORK, March 19 /PRNewswire/ -- Pfizer Inc (NYSE: PFE) announced today that launch plans are proceeding for Zithromax(TM) (azithromycin). Pfizer has begun shipping Zithromax to pharmacies.
 Zithromax, the first azalide antibiotic, is indicated for mild to moderate infections including:
 -- acute bacterial exacerbations of COPD (such as chronic bronchitis) due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae;
 -- streptococcal pharyngitis and tonsillitis due to Streptococcus pyogenes as an alternative to first-line penicillin therapy in patients who cannot use first-line therapy; Penicillin is the usual drug of choice in the treatment of S pyogenes infections and the prophylaxis of rheumatic fever.
 -- uncomplicated skin infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae;
 -- non-gonococcal urethritis and cervicitis due to Chlamydia trachomatis.
 The most common side effects are diarrhea, nausea, and abdominal pain. The pharmacokinetic profile of Zithromax (azithromycin) allows for once-daily full-course oral antibiotic therapy in half the usual time required by conventional antibiotics. Zithromax represents a breakthrough in convenience in oral antibiotic therapy.
 Zithromax is taken once-daily for only five days for indicated mild to moderate respiratory tract and skin infections. Most traditional therapies require 10 to 14 days of administration, usually with several daily doses. Medical professionals generally agree that a shorter, simpler course of antibiotic therapy improves the likelihood that patients will complete the full course of therapy.
 For non-gonococcal urethritis and cervicitis due to C trachomatis, a single oral dose of Zithromax is required, instead of two-to-four times a day for seven days with other drugs. This represents a breakthrough in therapy for this disease.
 Pfizer Labs, a division of Pfizer Inc is currently marketing Zithromax. Pfizer Inc is a diversified, research-based health care company with businesses in pharmaceuticals, hospital products, consumer products, animal health, and speciality chemicals and minerals. The company reported sales of more than $6.4 billion for 1990.
 -0- 3/19/92
 /CONTACT: Sherry Pudloski or Mary Curtin of Wang Associates Health Communications, 212-685-1900, Pfizer Labs/
 (PFE) CO: Pfizer Inc ST: New York IN: MTC SU: PDT


PS -- NY009 -- 9561 03/19/92 10:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1992
Words:354
Previous Article:GROWTH COMPANY CEOS SHORT ON SUCCESSION AND PERSONAL FINANCIAL PLANS, COOPERS & LYBRAND 'TRENDSETTER BAROMETER' FINDS
Next Article:WARNER BROS. STUDIO STORE HITS JACKPOT WITH LAS VEGAS LOCATION
Topics:


Related Articles
ZITHROMAX(R) (AZITHROMYCIN FOR ORAL SUSPENSION) APPROVED AS FIVE-DAY, ONCE-DAILY THERAPY FOR COMMON PEDIATRIC INFECTIONS
PFIZER RECEIVES CLEARANCE TO MARKET ZITHROMAX (AZITHROMYCIN) AS PREVENTION FOR A COMMON OPPORTUNISTIC INFECTION IN PERSONS WITH ADVANCED HIV INFECTION
Good News For Parents: The First and Only 5-Day, Once-Daily Children's Antibiotic Is Available for Common Pediatric Infections
Antibiotics down but not out in Atherosclerosis. (Subanalyses, Two Trials Pending).
Pfizer has agreed to pay out $6 million to 19 states, including Arkansas, to resolve allegations of misleading advertising for Zithromax, the world's...
Drug ad suit settled. (Policy & Practice).
Improve antibiotic compliance with short course.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters